Group 1: Company Performance - Moderna reported full-year 2025 revenue of $1.944 billion, a decrease of 39.23% year over year, with a net loss of $2.822 billion and negative free cash flow of $2.065 billion [2] - BioNTech achieved full-year 2025 revenue growth of 4.3% to €2.87 billion (approximately $3.25 billion), with €17.2 billion (approximately $19.4 billion) in cash and positive operating cash flow of €403 million (approximately $456 million) [5][11] - Novavax posted profitable results with an EPS of $0.11, significantly beating estimates of negative $0.42, and revenue rose 66.6% year over year to $147.14 million, largely due to a partnership with Sanofi [7][5] Group 2: Market Position and Analyst Sentiment - Moderna is currently trading 13.6% above the Wall Street consensus target of $43.75, despite its financial struggles [5] - BioNTech has strong analyst conviction with 14 Buys and a consensus target of $130.72, implying a 52.4% upside from the current price of $85.86 [12] - Novavax's stock is highly volatile with a beta of 2.63, and while it is currently profitable, its path to sustainable growth remains uncertain [9] Group 3: Future Prospects and Challenges - BioNTech's oncology pipeline includes multiple Phase 3 trials planned in partnership with Bristol Myers Squibb, indicating a robust future growth strategy [12] - Moderna's financials suggest a need for a recovery that has not yet materialized, raising concerns about its sustainability [6] - Novavax's reliance on partnerships for survival and negative shareholder equity present significant risks, despite its current profitability [9]